Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 2:53 PM ET

Healthcare Providers and Services

Company Overview of NewBridge Pharmaceuticals FZ-LLC

Company Overview

NewBridge Pharmaceuticals FZ-LLC, a specialty therapeutics company, focuses on pharmaceuticals, biologics, and medical diagnostics. It specializes in in-licensing, acquiring, registering, and commercializing to address the unmet medical needs of diseases with regional prevalence in the Middle East, Africa, Turkey, and Caspian regions. Its products include oncology and supportive care products, such as Abstral, a sublingual tablet for the treatment of pain in cancer patients; Clasteon, a bisphosphonate for the management of osteolysis resulting from bone metastases of malignant tumors, as well as for the management of hypercalcemia and bone pain of malignancy; Sancuso, a skin patch for the pr...

P.O. Box 500618

Business Central Tower A.

Office # 2405

Dubai Internet City

Dubai,  

United Arab Emirates

Founded in 2007

Phone:

971 44298700

Fax:

971 44298676

Key Executives for NewBridge Pharmaceuticals FZ-LLC

Chief Executive Officer, President and Director
Co-Founder and Vice President of Corporate Strategy & Business Development
Finance Director
Director of Regulatory, Quality & Government Affairs
Personal Assistant to President & Chief Executive Officer
Compensation as of Fiscal Year 2015.

NewBridge Pharmaceuticals FZ-LLC Key Developments

Eisai Plans to Market Halaven in Select Countries Within the Middle East Region Through New Partnership Between Eisai EMEA and NewBridge Pharmaceuticals

Eisai is planning to market Halaven (eribulin) in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. The product is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease.

Eisai EMEA Announces Partnership with NewBridge Pharmaceuticals to Market Breast Cancer Treatment Halaven(R) (Eribulin) Across the Middle East

Eisai announced that Halaven(R) (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for these treatments.

Similar Private Companies By Industry

Company Name Region
INDEX Medical Center Middle East/Africa
Wooridul Spine Centre Middle East/Africa
Conceive Gynecology & Fertility Centre Middle East/Africa
Mednet UAE FZ L.L.C. Middle East/Africa
Gulf Healthcare International LLC Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NewBridge Pharmaceuticals FZ-LLC, please visit nbpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.